CA-CROSSFIT
7.10.2019 13:02:09 CEST | Business Wire | Press release
At the conclusion of the 2020 Reebok CrossFit Games Open in October, CrossFit, Inc. will find the fittest man and woman in every eligible country participating in the worldwide CrossFit Open and crown them national champions. National champions automatically qualify for the 2020 Reebok CrossFit Games, held in August in Madison, Wisconsin. There, national champions will have the chance to compete with other Games athletes for $1.6M and the title of Fittest on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005216/en/
What Are the CrossFit Games?
The CrossFit Games are a grueling, multi-day competition in which elite athletes, ages 14 to 60+, and teams from around the world compete in the ultimate test of fitness. The CrossFit Games are the Sport of Fitness, and well-rounded athletes train to be prepared for unknown events announced just before the competition. CrossFit movements are selected from gymnastics, powerlifting, Olympic lifting, running, rowing, and beyond.
Athletes arrive in Madison, Wisconsin, with almost no knowledge of the actual events, so their training has to cover a wider range of activities than any other professional sport. They are ranked during competition with their peers, and the winners are crowned Fittest on Earth after proving their fitness in a series of diverse events over the course of several days. The 2020 event will be the 13th annual edition of the CrossFit Games and the largest field of individual athletes ever. The total purse this year is more than $2.3M.
What Is the CrossFit Games Open?
The CrossFit Games Open is the largest fitness competition on Earth and the first of three competitions that form the CrossFit Games season: the Open, the Age Group Online Qualifier, and the Games. In the Open, hundreds of thousands of athletes from more than 15,000 CrossFit affiliates worldwide compete in a five-week test of fitness. This online competition is open to anyone in the world. Every week, from Oct. 10, 2019, to Nov. 11, 2019, athletes will complete a workout designed by CrossFit, Inc. to test cardiovascular/respiratory endurance, stamina, strength, flexibility, power, coordination, agility, balance, and accuracy.
Upon completion of the Open, the top 20 athletes worldwide, as well as the first-place male and female competitors from each eligible country, will earn invitations to compete at the 2020 Reebok CrossFit Games. Following the Open, top age group athletes from 14-17 and 35-60+ have a second online qualifier to earn an Age Group spot in the finals. Beyond these two online qualifiers, the only way for an athlete to guarantee a spot in the finals is to win one of the 28 Sanctionals™ (CrossFit competitions that are individually owned and operated).
CrossFit Games Open National Champions
The 2020 season will mark the second year in which CrossFit, Inc. awards the first-place man and woman in every eligible nation worldwide the opportunity to compete at the CrossFit Games.
In 2019, CrossFit crowned a total of 232 national champions hailing from 123 different countries. On Thursday, Aug. 1, 2019, the first day of competition in Madison, Wisconsin, 143 men and 117 women representing 114 countries took the field, becoming the most diverse field of athletes the CrossFit Games had ever seen.
From Afghanistan to Belgium, Egypt to Estonia, Kosovo to Kuwait — the National Champion Open qualifier gives athletes from nations where CrossFit is in its infancy the opportunity to evolve the sport and represent their countries on a worldwide stage.
There are virtually no barriers to entry for any athlete who wishes to represent their country at the 2020 Reebok CrossFit Games. No professional status or allegiance to a sport federation is required or even preferred. Athletes need only do the following:
- Register for the Open.
- Complete and video record all five Open workouts as prescribed over the course of the Open. Submit scores to games.crossfit.com.
Champions will be notified after the Leaderboard is set upon completion of the Open and after citizenship is verified.
About CrossFit, Inc.
CrossFit, Inc. is the developer and provider of the CrossFit® fitness program and a recognized worldwide leader in functional fitness. Founded by Greg Glassman and built on the foundations of constantly varied, high-intensity functional movements, education and collaborative competition, CrossFit-brand workouts develop strength and fitness while cultivating community and camaraderie in each of the more than 15,000 affiliated gyms in CrossFit’s global network. CrossFit, Inc. is a leading accredited certificate issuer for physical-training professionals worldwide and offers specialty certificate programs in addition to its core curriculum. CrossFit, Inc.’s health initiatives pursue an investigation into the ills of modern medicine and the willful abuse of the public’s trust in science. CrossFit, Inc. created and operates the CrossFit Games, an annual competition where elite athletes compete to be named the Fittest on Earth™. To learn more, visit www.CrossFit.com , Games.CrossFit.com , or http://www.youtube.com/CrossFitHQ.
CrossFit, Forging Elite Fitness, The Sport of Fitness and Fittest on Earth are registered trademarks or trademarks of CrossFit, Inc. in the U.S. and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005216/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom